Immune privilege in the anterior chamber of the eye

Critical Reviews in Immunology

Volumn 22, Issue 1, 2002, Pages 13-46

  Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anterior chamber; Cornea; Eye immune privilege; Transplantation

Indexed keywords

CYTOKINE; FAS LIGAND;

ADAPTATION; ANTERIOR EYE CHAMBER; ANTIGEN SPECIFICITY; APOPTOSIS; CELL INFILTRATION; CELL PROLIFERATION; CORNEA TRANSPLANTATION; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATION; LYMPHATIC DRAINAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; VISION; ANIMAL; EYE; GRAFT SURVIVAL; IMMUNOLOGY;

ANIMAL; ANTERIOR CHAMBER; CORNEAL TRANSPLANTATION; EYE; GRAFT SURVIVAL; HUMAN; IMMUNE TOLERANCE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS;

EID: 0036022188     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (251)

1. Germinating seed in anterior chamber. Report of an unusual case
2. Die entwicklung der in fremden grand versetzten lebenden geweba. Albrecht von Graefes
3. The heterologous transplantation of human cancers
4. Quantitative studies on tissue transplantation immunity. II. The origin, strength, and duration of actively and adoptively acquired immunity
5. A second study of the behavior and fate of skin homografts in rabbits
6. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye
7. Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells
8. Immune response to immunization via the anterior chamber of the eye. I. F. lymphocyte-induced immune deviation
9. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice
10. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens
11. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen
12. Role of suppressor T cells in herpes simplex virus-induced immune deviation
13. Anterior chamber-associated immune deviation induced by soluble antigens
14. Histopathologic analysis of experimental autoimmune uveitis attenuated by intracameral injection of S-antigen
15. Induction of anterior chamber-associated immune deviation with lymphoreticular allogeneic cells
16. Alloantigens introduced into the anterior chamber of the eye induce systemic suppression of delayed hypersensitivity to third-party alloantigens through "linked recognition"
17. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis
18. Blood mononuclear cells induce regulatory NKT thymocytes in anterior chamber-associated immune deviation
19. Suppressed cellular immunity in mice harboring intraocular melanomas
20. A novel role for TGF-beta and IL-10 in the induction of immune privilege
21. The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response
22. Suppression of experimental autoimmune uveitis in mice by induction of anterior chamber-associated immune deviation with interphotoreceptor retinoid-binding protein
23. Spontaneous immune rejection of intraocular tumors in mice
24. In situ suppression of delayed-type hypersensitivity another mechanism for sustaining the immune privilege of the anterior chamber
25. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors
26. The presence of donor-derived class II-positive cells abolishes immune privilege in the anterior chamber of the eye
27. Capacity of simian virus 40 T antigen to induce self-tolerance but not immunological privilege in the anterior chamber of the eye
28. Immune privilege in the anterior chamber of the eye is not extended to intraocular Listeria monocytogenes
29. Blood-borne signals that induce anterior chamber-associated immune deviation after intracameral injection of antigen
30. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells
31. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation
32. Role of Th1 and Th2 cells in anterior chamber-associated immune deviation
33. NKT cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance
34. Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type
35. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1
36. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site
37. Anterior chamber-associated immune deviation
38. Immune privilege and immune regulation in the eye
39. Regional differences in immune regulation: The immunogenic privilege of corneal allografts
40. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments
41. A vision of cell death: Insights into immune privilege
42. Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations
43. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells
44. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses
45. Intracamerally induced concomitant immunity: Mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge
46. Distinctive humoral immune responses following anterior chamber and intravenous administration of soluble antigen. Evidence for active suppression of IgG2-secreting B lymphocytes
47. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases
48. Intracameral inoculation of herpes simplex virus type I induces anterior chamber associated immune deviation
49. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance
50. Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)-microglobulin-deficient BALB/c mice
51. The differing patterns of antigen release and local retention following anterior chamber and intravenous inoculation of soluble antigen. Evidence that the eye acts as an antigen depot
52. A splenic requirement for the generation of suppressor T cells
53. Split T-cell tolerance in herpes simplex virus-infected mice and its implication for antiviral immunity
54. Tolerance and suppression of immunity to herpes simplex virus: Different presentations of antigens induce different types of suppressor cells
55. The fate of anterior chamber flurescein in the monkey eye. 1. The anterior chamber outflow pathways
56. Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site
57. In-vivo impaired T helper 1 cell development in submandibular lymph nodes due to IL-12 deficiency following antigen injection into the anterior chamber of the eye
58. Ocular immunosuppressive microenvironment
59. Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity
60. Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells
61. Fas ligand-induced apoptosis as a mechanism of immune privilege
62. Anterior chamber inoculation of splenocytes without Fas/Fas-ligand interaction primes for a delayed-type hypersensitivity response rather than inducing anterior chamber-associated immune deviation
63. Regulation of fas ligand-induced apoptosis by tnf
64. The role of T cell apoptosis in transplantation tolerance
65. Evidence for multiple CD95-CD95 ligand interactions in anterior chamber-associated immune deviation induced by soluble protein antigen
66. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood
67. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta
68. Direct thymic involvement in anterior chamber-associated immune deviation: Evidence for a nondeletional mechanism of centrally induced tolerance to extrathymic antigens in adult mice
69. Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID
70. Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties
71. + T cells similar to those found in mice with anterior chamber-associated immune deviation
72. MIP-2 recruits NKT cells to the spleen during tolerance induction
73. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens
74. Antigen presentation in acquired immunological tolerance
75. Do small B cells induce tolerance?
76. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations
77. Role of splenic B cells in the immune privilege of the anterior chamber of the eye
78. Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID)
79. Suppression of immune responses by CD8 cells. II. Qa-1 on activated B cells stimulates CD8 cell suppression of T helper 2 responses
80. The Qa-1 antigenic system. Relation of Qa-1 phenotypes to lymphocyte sets, mitogen responses, and immune functions
81. Evidence for antigen presentation by the class Ib molecule, Qa-1
82. + T cells restricted by the MHC class Ib molecule, Qa-1
83. T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells
84. CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells
85. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes
86. + cells suppress experimental autoimmune uveitis
87. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance
88. Suppression of cytotoxic T lymphocyte activity by gamma/delta T cells in tumor-bearing mice
89. Down-regulation of tumoricidal NK and NKT cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions
90. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells
91. Gamma delta T cells are needed for ocular immune privilege and corneal graft survival
92. γδ T cells are critical for the induction of anterior chamber-associated immune deviation
93. Alterations in cytokine production following intraocular injection of soluble protein antigen: Impairment in IFN-gamma and induction of TGF-beta and IL-4 production
94. Local production of IFN-gamma abrogates the intraocular immune privilege in transgenic mice and prevents the induction of ACAID
95. Analysis of in vivo regulatory properties of T cells activated in vitro by TGFbeta2-treated antigen presenting cells
96. Regulatory T cells in the control of immune pathology
97. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
98. + T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta
99. + cells are genetically restricted effectors and their production requires CD4 and I-A expression
100. + suppressor-inducer T cells
101. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production
102. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10
103. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation
104. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
105. Growth factors in aqueous humor of normal and inflamed eyes of rabbits
106. Inhibition of lymphocyte proliferation by aqueous humor
107. Efferent blockade of delayed-type hypersensitivity responses in the anterior chamber of the eye
108. Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye
109. Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor
110. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor
111. Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon
112. Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation
113. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor
114. Effect of aqueous humor on apoptosis of inflammatory cell types
115. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis
116. Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness
117. Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells
118. Expression of HLA-A/B/C and -DR locus antigens on epithelial, stromal, and endothelial cells from the human cornea
119. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye
120. The RMA-S lymphoma mutant; consequences of a peptide loading defect on immunological recognition and graft rejection
121. Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells
122. Cutting edge: Role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege J Immunol
123. Absence of MHC gene expression in lens and cloning of dbpB/YB-1, a DNA-binding protein expressed in mouse lens
124. A macrophage migration inhibitory factro is expressed in the differentiating cells of the eye lens
125. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model
126. Infiltrating lymphocytes and antigen expression in uveal melanoma
127. HLA expression and tumorinfiltrating immune cells in uveal melanoma
128. Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma
129. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors
130. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland
131. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59
132. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody dependent complement activation
133. Complement levels in normal and inflamed aqueous humor
134. Alternate and classical pathway components of complement in the normal cornea
135. Complement inhibitors in normal cornea and aqueous humor
136. Quantitative determinations of complement components and immunoglobulins in tears and aqueous humor
137. Differential expression of the complement regulatory proteins in the human eye
138. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins
139. The pharmacology of T cell apoptosis
140. A role for CD95 ligand in preventing graft rejection
141. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus
142. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival
143. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants
144. HLA class I chromosomal region, genes, and products: Facts and questions
145. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cyrolysis
146. Proinflammatory and immunoregulatory functions of interleukin-12
147. HLA-G a shield against inflammatory aggression
148. Multiple products of class Ib Qa-2 genes which ones are functional?
149. Tissue-specific, peptide-binding transplantation antigens: Lessons from the Qa-2 system
150. Expression of a nonclassical MHC class Ib molecule in the eye
151. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation
152. The immunology of corneal transplantation
153. Eine erfolgreiche totale keratoplastik. Albrecht von Graefes
154. Characteristics of rejection of orthotopic corneal allografts in the rat
155. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply
156. The role of FasL-induced apoptosis in immune privilege
157. T-cell subsets, bm mutants, and the mechanisms of allogeneic skin graft rejection
158. Class I disparate corneal grafts enjoy afferent but not efferent blockade of the immune response
159. Evidence that the fate of class II-disparate corneal grafts is determined by the timing of class II expression
160. The distribution of HLA antigens on human corneal tissue
161. The differential effects of donor versus host Langerhans cells in the rejection of MHC-matched corneal allografts
162. The relative immunogenicity of corneal epithelium, stroma, and endothelium. The role of major histocompatibility complex antigens
163. Sex chromatin as a biologic cell marker in the study of the fate of corneal transplants
164. The influence of donor-recipient sensitization on corneal grafts
165. Dynamics of donor cell persistence and recipient cell replacement in orthotopic corneal allografts in mice
166. Antigen processing and presentation in transplantation
167. Role of donor specific cytotoxic T cells in rejection of corneal allografts in normal and high-risk eyes
168. Heterotopic corneal grafting in mice: A new approach to the study of corneal alloimmunity
169. T cell subsets in the immune rejection of murine heterotopic corneal allografts
170. Antigen presentation by Langerhans cells in vivo: Donor-derived Ia* Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens
171. Regulation of delayed-type hypersensitivity. VI. Antigen-specific suppressor T cells and suppressor factor for delayed-type hypersensitivity to histocompatibility antigens
172. The role of afferent lymphatics in the rejection of skin homografts
173. Lymphatic drainage from vascularized rabbit cornea
174. Function and cell surface phenotype of dendritic cells from rat cornea
175. Topical interleukin 1 receptor antagonist promotes corneal transplant survival
176. Dendritic cells and the control of immunity
177. The immune privilege of corneal allografts
178. Depletion of donor-derived Langerhans cells promotes corneal allograft survival
179. Penetrating corneal transplantation in the inbred rat: A new model
180. Contribution of direct and indirect recognition pathways to T cell alloreactivity
181. + T cells in immunobiology of orthotopic corneal transplants in mice
182. Role of CD4(+) and CD8(+) T cells in allorecognition: Lessons from corneal transplantation
183. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate
184. Oral immunization induces protective immunity against Alcanthamoeba keratitis
185. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts
186. Anterior chamber-associated immune deviation promotes corneal allograft survival
187. Long term survival of corneal allografts is dependent on intact CD1d reactive NKT cells
188. Intracameral injection of allogeneic lymphocytes enhances corneal graft survival
189. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice
190. Corneal transplantation in antibody-deficient hosts
191. Effect of alloantibodies on cornal allograft survival
192. Hypersensitiveness to lens protein; patient desensitized and successfully operated on for immature cataract
193. Sympathetic ophthalmia in Canada
194. The immune response to homologous lens crystallin. I. Antibody production after lens injury
195. The immune response to homologous lens crystallin. II. A model of ocular inflammation involving eye injuries at separate times
196. The role of autoimmune phenomena in the pathogenesis of cataract
197. The lens opacities classification system III
198. No immunoglobulins in cataractous lenses
199. The humoral response to alpha, beta, and gamma crystallins of the human lens
200. Anti-lens antibody in human sera
201. Anti-beta-crystallin antibodies (mouse) or sera from humans with age-related cataract are cytotoxic for lens epithelial cells in culture
202. The ocular lens
203. Expression of ocular autoantigens in the mouse thymus
204. Thymic expression of autoantigens correlates with resistance to autoimmune disease
205. Studien zur sympathischen ophthalmie. 2. Die antigene wirkung des augenpigmentes. Albrecth von Graefes
206. Experimental allergic uveitis: Homologous retina as uveitogenic antigen
207. Purification and characterization of a retinol-binding glycoprotein synthesized and secreted by bovine neural retina
208. Vitamin A transport between retina and pigment epithelium-an interstitial protein carrying endogenous retinol (interstitial retinol-binding protein)
209. Autoimmunity and the retina
210. Experimental autoimmune uveitis in the athymic nude rat
211. Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats
212. Induction of experimental autoimmune uveoretinitis by T-cell lines
213. Adoptive transfer of experimental autoimmune uveoretinitis in rats. Immunopathogenic mechanisms and histologic features
214. Lymphocyte responses to retinal-specific antigens in uveitis patients and healthy subjects
215. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens
216. Organ resident, nonlymphoid cells suppress proliferation of autoimmune T-helper lymphocytes
217. Specific aqueous humor factors induce activation of regulatory T cells
218. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis
219. Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis
220. Induction of anterior chamber associated immune deviation in rats receiving intracameral injections of retinal S antigen
221. Characterization of a suppressor cell line which downgrades experimental autoimmune uveoretinitis in the rat
222. Immunopathology of onchocerciasis: A role for eosinophils in onchocercal dermatitis and keratitis
223. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982
224. Immunological barriers in the eye
225. Immunity causing blindness: Five different paths to herpes stromal keratitis
226. Herpetic keratitis in athymic (nude) mice
227. Cell-mediated immune tolerance to HSV-1 antigens associated with reduced susceptibility to HSV-1 corneal lesions
228. Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis
229. Phenotypic and functional studies on ocular T cells during herpetic infections of the eye
230. + T lymphocytes
231. Immunopathology of herpes simplex virus infections
232. Critical role of corneal Langerhans cells in the CD4- but not CD8 mediated immunopathology in herpes simplex virus-1-infected mouse corneas
233. Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1
234. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10
235. Importance of reinfection in the pathogenesis of trachoma
236. Experimental trachoma in owl monkeys
237. Nonculture methods for diagnosing chlamydial infection in patients with trachoma: A clue to the pathogenesis of the disease?
238. Ocular delayed hypersensitivity: A pathogenetic mechanism of chlamydial-conjunctivitis in guinea pigs
239. Chlamydia-specific lymphocytes in conjunctiva during ocular infection: Limiting dilution analysis
240. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring
241. An essential role for antibody in neutrophil and eosinophil recruitment to the cornea: B cell-deficient (microMT) mice fail to develop Th2-dependent, helminth-mediated keratitis
242. A dominant role for Fc gamma receptors in antibody-dependent corneal inflammation
243. Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology
244. Eosinophil granule major basic protein inhibition of corneal epithelial wound healing
245. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye
246. Rejection of intraocular tumors from transgenic mice by tumor infiltrating lymphocytes
247. Successful immunotherapy of an intraocular tumor in mice
248. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis
249. Structure and function of the cornea